The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer
Purpose Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2018-02, Vol.45 (2), p.170-178 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 170 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 45 |
| creator | Kim, Ka-Rham Shim, Hyun-Jeong Hwang, Jun-Eul Cho, Sang-Hee Chung, Ik-Joo Park, Ki Seong Kang, Sae-Ryung Kwon, Seong Young Chung, Woong-Ki Bae, Woo Kyun |
| description | Purpose
Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will benefit more from surgery than from CCRT. We investigated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) after ICT to predict the efficacy of CCRT and clinical outcomes.
Methods
Tumor responses were retrospectively reviewed after CCRT based on the Response Evaluation Criteria in Solid Tumors. FDG PET-CT imaging was performed before and after three cycles of TPF. We examined the associations between the metabolic response (percentage decrease in the maximum standardized uptake value [SUVmax] and total metabolic tumor volume [MTV]) after ICT and complete response (CR) to CCRT, progression-free survival (PFS), and overall survival (OS).
Results
We studied 43 HNC patients with a median follow-up of 32.7 months. Lymph node (LN) SUVmax and total MTV decreases from baseline after ICT were greater in patients with a CR to CCRT than in non-CR patients (LN SUVmax, 88.8% vs. 62.5%, respectively; total MTV, 99.7% vs. 89.9%, respectively). Decreases in total MTV ≥ 78% and LN SUVmax ≥73% after ICT predicted CR to CCRT and longer OS and PFS.
Conclusions
Using interim FDG PET-CT to measure SUVmax and total MTV after three cycles of ICT may be a useful technique for identifying HNC patients who will benefit from CCRT and predicting survival outcomes. |
| doi_str_mv | 10.1007/s00259-017-3836-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5745569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1981649652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-ac6dc14a22c5203e04482debf48b1367a9257291d182c340dc2e1305b68652a63</originalsourceid><addsrcrecordid>eNp1kc2OFCEUhYnROD_6AG4MiRs3pUBRBbUxMe3MaDKJLto1oeFWF2M1tFA1ybyKT-vtqbEzmrgBwv3O4V4OIa84e8cZU-8LY6LpKsZVVeu6rfQTcspb3lWK6e7p8azYCTkr5YYxroXunpMTXCXjjJ-SX-sBaE4j0NTTECfIYUcvP13RbxfrarWmtscrLPjZTSFF6gbYpWmAbPd31BZq6T6DD25K-eDgUnRzzhCnhczWhyMOfR-cdaiLHmVpG1MJhfYoHcD6--sI7gd1NjrIL8iz3o4FXj7s5-T75cV69bm6_nr1ZfXxunJSsamyrvWOSyuEawSrgUmphYdNL_WG162ynWiU6LjH4V0tmXcCeM2aTavbRti2PicfFt_9vNmBd9h8tqPZ40_YfGeSDebvSgyD2aZb0yjZNG2HBm8fDHL6OUOZzC4UB-NoI6S5GN5JobAtdUDf_IPepDlHHA8pzVvZYU9I8YVyOZWSoT82w5k5JG-W5A0mbw7JG42a14-nOCr-RI2AWICCpbiF_Ojp_7r-BoQuuuU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1981649652</pqid></control><display><type>article</type><title>The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer</title><source>Springer Nature - Complete Springer Journals</source><creator>Kim, Ka-Rham ; Shim, Hyun-Jeong ; Hwang, Jun-Eul ; Cho, Sang-Hee ; Chung, Ik-Joo ; Park, Ki Seong ; Kang, Sae-Ryung ; Kwon, Seong Young ; Chung, Woong-Ki ; Bae, Woo Kyun</creator><creatorcontrib>Kim, Ka-Rham ; Shim, Hyun-Jeong ; Hwang, Jun-Eul ; Cho, Sang-Hee ; Chung, Ik-Joo ; Park, Ki Seong ; Kang, Sae-Ryung ; Kwon, Seong Young ; Chung, Woong-Ki ; Bae, Woo Kyun</creatorcontrib><description>Purpose
Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will benefit more from surgery than from CCRT. We investigated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) after ICT to predict the efficacy of CCRT and clinical outcomes.
Methods
Tumor responses were retrospectively reviewed after CCRT based on the Response Evaluation Criteria in Solid Tumors. FDG PET-CT imaging was performed before and after three cycles of TPF. We examined the associations between the metabolic response (percentage decrease in the maximum standardized uptake value [SUVmax] and total metabolic tumor volume [MTV]) after ICT and complete response (CR) to CCRT, progression-free survival (PFS), and overall survival (OS).
Results
We studied 43 HNC patients with a median follow-up of 32.7 months. Lymph node (LN) SUVmax and total MTV decreases from baseline after ICT were greater in patients with a CR to CCRT than in non-CR patients (LN SUVmax, 88.8% vs. 62.5%, respectively; total MTV, 99.7% vs. 89.9%, respectively). Decreases in total MTV ≥ 78% and LN SUVmax ≥73% after ICT predicted CR to CCRT and longer OS and PFS.
Conclusions
Using interim FDG PET-CT to measure SUVmax and total MTV after three cycles of ICT may be a useful technique for identifying HNC patients who will benefit from CCRT and predicting survival outcomes.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-017-3836-8</identifier><identifier>PMID: 28940101</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>5-Fluorouracil ; Cancer ; Cardiology ; Chemoradiotherapy ; Chemotherapy ; Cisplatin ; Computed tomography ; Effectiveness ; Emission analysis ; Head & neck cancer ; Imaging ; Information technology ; Lymph nodes ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metabolic response ; Metabolism ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Predictions ; Preservation ; Radiation therapy ; Radiology ; Solid tumors ; Surgery ; Survival ; Tomography ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2018-02, Vol.45 (2), p.170-178</ispartof><rights>The Author(s) 2017</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-ac6dc14a22c5203e04482debf48b1367a9257291d182c340dc2e1305b68652a63</citedby><cites>FETCH-LOGICAL-c470t-ac6dc14a22c5203e04482debf48b1367a9257291d182c340dc2e1305b68652a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-017-3836-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-017-3836-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28940101$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Ka-Rham</creatorcontrib><creatorcontrib>Shim, Hyun-Jeong</creatorcontrib><creatorcontrib>Hwang, Jun-Eul</creatorcontrib><creatorcontrib>Cho, Sang-Hee</creatorcontrib><creatorcontrib>Chung, Ik-Joo</creatorcontrib><creatorcontrib>Park, Ki Seong</creatorcontrib><creatorcontrib>Kang, Sae-Ryung</creatorcontrib><creatorcontrib>Kwon, Seong Young</creatorcontrib><creatorcontrib>Chung, Woong-Ki</creatorcontrib><creatorcontrib>Bae, Woo Kyun</creatorcontrib><title>The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will benefit more from surgery than from CCRT. We investigated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) after ICT to predict the efficacy of CCRT and clinical outcomes.
Methods
Tumor responses were retrospectively reviewed after CCRT based on the Response Evaluation Criteria in Solid Tumors. FDG PET-CT imaging was performed before and after three cycles of TPF. We examined the associations between the metabolic response (percentage decrease in the maximum standardized uptake value [SUVmax] and total metabolic tumor volume [MTV]) after ICT and complete response (CR) to CCRT, progression-free survival (PFS), and overall survival (OS).
Results
We studied 43 HNC patients with a median follow-up of 32.7 months. Lymph node (LN) SUVmax and total MTV decreases from baseline after ICT were greater in patients with a CR to CCRT than in non-CR patients (LN SUVmax, 88.8% vs. 62.5%, respectively; total MTV, 99.7% vs. 89.9%, respectively). Decreases in total MTV ≥ 78% and LN SUVmax ≥73% after ICT predicted CR to CCRT and longer OS and PFS.
Conclusions
Using interim FDG PET-CT to measure SUVmax and total MTV after three cycles of ICT may be a useful technique for identifying HNC patients who will benefit from CCRT and predicting survival outcomes.</description><subject>5-Fluorouracil</subject><subject>Cancer</subject><subject>Cardiology</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Computed tomography</subject><subject>Effectiveness</subject><subject>Emission analysis</subject><subject>Head & neck cancer</subject><subject>Imaging</subject><subject>Information technology</subject><subject>Lymph nodes</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic response</subject><subject>Metabolism</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Predictions</subject><subject>Preservation</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>Solid tumors</subject><subject>Surgery</subject><subject>Survival</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc2OFCEUhYnROD_6AG4MiRs3pUBRBbUxMe3MaDKJLto1oeFWF2M1tFA1ybyKT-vtqbEzmrgBwv3O4V4OIa84e8cZU-8LY6LpKsZVVeu6rfQTcspb3lWK6e7p8azYCTkr5YYxroXunpMTXCXjjJ-SX-sBaE4j0NTTECfIYUcvP13RbxfrarWmtscrLPjZTSFF6gbYpWmAbPd31BZq6T6DD25K-eDgUnRzzhCnhczWhyMOfR-cdaiLHmVpG1MJhfYoHcD6--sI7gd1NjrIL8iz3o4FXj7s5-T75cV69bm6_nr1ZfXxunJSsamyrvWOSyuEawSrgUmphYdNL_WG162ynWiU6LjH4V0tmXcCeM2aTavbRti2PicfFt_9vNmBd9h8tqPZ40_YfGeSDebvSgyD2aZb0yjZNG2HBm8fDHL6OUOZzC4UB-NoI6S5GN5JobAtdUDf_IPepDlHHA8pzVvZYU9I8YVyOZWSoT82w5k5JG-W5A0mbw7JG42a14-nOCr-RI2AWICCpbiF_Ojp_7r-BoQuuuU</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Kim, Ka-Rham</creator><creator>Shim, Hyun-Jeong</creator><creator>Hwang, Jun-Eul</creator><creator>Cho, Sang-Hee</creator><creator>Chung, Ik-Joo</creator><creator>Park, Ki Seong</creator><creator>Kang, Sae-Ryung</creator><creator>Kwon, Seong Young</creator><creator>Chung, Woong-Ki</creator><creator>Bae, Woo Kyun</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180201</creationdate><title>The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer</title><author>Kim, Ka-Rham ; Shim, Hyun-Jeong ; Hwang, Jun-Eul ; Cho, Sang-Hee ; Chung, Ik-Joo ; Park, Ki Seong ; Kang, Sae-Ryung ; Kwon, Seong Young ; Chung, Woong-Ki ; Bae, Woo Kyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-ac6dc14a22c5203e04482debf48b1367a9257291d182c340dc2e1305b68652a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>5-Fluorouracil</topic><topic>Cancer</topic><topic>Cardiology</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Computed tomography</topic><topic>Effectiveness</topic><topic>Emission analysis</topic><topic>Head & neck cancer</topic><topic>Imaging</topic><topic>Information technology</topic><topic>Lymph nodes</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic response</topic><topic>Metabolism</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Predictions</topic><topic>Preservation</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>Solid tumors</topic><topic>Surgery</topic><topic>Survival</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Ka-Rham</creatorcontrib><creatorcontrib>Shim, Hyun-Jeong</creatorcontrib><creatorcontrib>Hwang, Jun-Eul</creatorcontrib><creatorcontrib>Cho, Sang-Hee</creatorcontrib><creatorcontrib>Chung, Ik-Joo</creatorcontrib><creatorcontrib>Park, Ki Seong</creatorcontrib><creatorcontrib>Kang, Sae-Ryung</creatorcontrib><creatorcontrib>Kwon, Seong Young</creatorcontrib><creatorcontrib>Chung, Woong-Ki</creatorcontrib><creatorcontrib>Bae, Woo Kyun</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Ka-Rham</au><au>Shim, Hyun-Jeong</au><au>Hwang, Jun-Eul</au><au>Cho, Sang-Hee</au><au>Chung, Ik-Joo</au><au>Park, Ki Seong</au><au>Kang, Sae-Ryung</au><au>Kwon, Seong Young</au><au>Chung, Woong-Ki</au><au>Bae, Woo Kyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>45</volume><issue>2</issue><spage>170</spage><epage>178</epage><pages>170-178</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Induction chemotherapy (ICT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT) has the advantages of organ preservation and systemic control in head and neck cancer (HNC). Early prediction of CCRT efficacy may help identify patients who will benefit more from surgery than from CCRT. We investigated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) after ICT to predict the efficacy of CCRT and clinical outcomes.
Methods
Tumor responses were retrospectively reviewed after CCRT based on the Response Evaluation Criteria in Solid Tumors. FDG PET-CT imaging was performed before and after three cycles of TPF. We examined the associations between the metabolic response (percentage decrease in the maximum standardized uptake value [SUVmax] and total metabolic tumor volume [MTV]) after ICT and complete response (CR) to CCRT, progression-free survival (PFS), and overall survival (OS).
Results
We studied 43 HNC patients with a median follow-up of 32.7 months. Lymph node (LN) SUVmax and total MTV decreases from baseline after ICT were greater in patients with a CR to CCRT than in non-CR patients (LN SUVmax, 88.8% vs. 62.5%, respectively; total MTV, 99.7% vs. 89.9%, respectively). Decreases in total MTV ≥ 78% and LN SUVmax ≥73% after ICT predicted CR to CCRT and longer OS and PFS.
Conclusions
Using interim FDG PET-CT to measure SUVmax and total MTV after three cycles of ICT may be a useful technique for identifying HNC patients who will benefit from CCRT and predicting survival outcomes.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28940101</pmid><doi>10.1007/s00259-017-3836-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2018-02, Vol.45 (2), p.170-178 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5745569 |
| source | Springer Nature - Complete Springer Journals |
| subjects | 5-Fluorouracil Cancer Cardiology Chemoradiotherapy Chemotherapy Cisplatin Computed tomography Effectiveness Emission analysis Head & neck cancer Imaging Information technology Lymph nodes Medical prognosis Medicine Medicine & Public Health Metabolic response Metabolism Nuclear Medicine Oncology Original Original Article Orthopedics Patients Positron emission Positron emission tomography Predictions Preservation Radiation therapy Radiology Solid tumors Surgery Survival Tomography Tumors |
| title | The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T13%3A43%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20interim%20FDG%20PET-CT%20after%20induction%20chemotherapy%20as%20a%20predictor%20of%20concurrent%20chemoradiotherapy%20efficacy%20and%20prognosis%20for%20head%20and%20neck%20cancer&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Kim,%20Ka-Rham&rft.date=2018-02-01&rft.volume=45&rft.issue=2&rft.spage=170&rft.epage=178&rft.pages=170-178&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-017-3836-8&rft_dat=%3Cproquest_pubme%3E1981649652%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1981649652&rft_id=info:pmid/28940101&rfr_iscdi=true |